Biocryst Pharma Inc (BCRX) |
|
11.44 -0.43 (-3.62%)
|
12-05 00:48 |
|
Open: |
11.845 |
Pre. Close: |
11.87 |
|
High:
|
11.97 |
Low:
|
11.22 |
|
Volume:
|
2,277,585 |
Market Cap:
|
2,058M |
|
|
|
|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.004 - 12.07 |
12.07 - 12.124 |
|
Low:
|
11.022 - 11.113 |
11.113 - 11.186 |
|
Close:
|
11.305 - 11.441 |
11.441 - 11.552 |
|
Technical analysis |
as of: 2021-12-03 4:42:00 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 16.18 One year: 18.08 |
| Support: |
Support1: 11.22 Support2: 9.34 |
| Resistance: |
Resistance1: 13.85 Resistance2: 15.48 |
| Pivot: |
12.07 |
| Moving Average: |
MA(5): 11.82 MA(20): 12.18
MA(100): 14.66 MA(250): 12.95  |
| MACD: |
MACD(12,26): -0.52 Signal(9): -0.53 |
| Stochastic oscillator: |
%K(14,3): 14.92 %D(3): 23.34 |
| RSI: |
RSI(14): 37.45 |
| 52-week: |
High: 18.48 Low: 6.83 Change(%): 49.3 |
| Average Vol(K): |
3-Month: 273729 10-Days: 275971 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.BCRX has closed above bottom band by 8.8%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to BCRX's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 03 Dec 2021
BioCryst announces inducement grants to 11 new employees - Seeking Alpha
Tue, 30 Nov 2021
Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics - Nasdaq
Mon, 29 Nov 2021
3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire - The Motley Fool
Mon, 22 Nov 2021
Health Care Sector Update for 11/22/2021: BCRX,RPRX,ALNY,AFMD,AUPH - Nasdaq
Mon, 22 Nov 2021
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals - Yahoo Finance
Fri, 12 Nov 2021
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
180 |
| Shares Float (M) |
166 |
|
% Held by Insiders
|
0.90 |
|
% Held by Institutions
|
59.95 |
|
Shares Short (K)
|
18,970 |
|
Shares Short P. Month (K)
|
18,980 |
Stock Financials |
|
EPS
|
-1.270 |
|
EPS Est This Year
|
-0.750 |
|
EPS Est Next Year
|
-0.780 |
|
Book Value (p.s.)
|
-0.590 |
|
Profit Margin
|
-198.88 |
|
Operating Margin
|
-156.06 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
571.8 |
|
Gross Profit (p.s.)
|
-0.594 |
|
Sales Per Share
|
0.634 |
|
EBITDA (p.s.)
|
-0.985 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
-9.01 |
|
PEG Ratio
|
|
|
Price to Book value
|
-19.39 |
|
Price to Sales
|
18.04 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
